Joint Care Tablet 2.0
Natural health product licensed in Canada
- Licence holder
- Aersun Technology Ltd.
- NPN or DIN-HM
- 80089441
- Status
- Active licence
- Licence date
- 5 December 2018
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Boswellia serrata Source : Stem bark oleogum resin Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 500 milligramme Potency : 40 % Boswellic acids | 50 milligramme | Not calculated |
| Sulfate de chondroïtine Source : Bos taurus - cartilage | 200 milligramme | Not calculated |
| Acide hyaluronique Source : Streptococcus equi - capsule extracellulaire bactérienne | 7.5 milligramme | Not calculated |
| Manganèse | 0.75 milligramme | 1,500 µg |
| Curcuma longa Source : Rhizome Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 200 milligramme | 20 milligramme | Not calculated |
| Bore | 0.225 milligramme | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Croscarmellose de sodium, Acide stéarique, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Comprimé | 2 Tous les jours |
Uses authorised in Canada
Helps to relieve joint pain associated with osteoarthritis (of the knee). Helps to protect against the deterioration of cartilage. A factor in maintaining healthy cartilage and/or joint health. Helps in the development and maintenance of bones.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity (e.g. allergy) has been known to occur; in which case, discontinue use. Some people may experience mild gastrointestinal disturbances such as diarrhoea, abdominal pain, heartburn, nausea and vomiting; in which case, discontinue use.
- Précautions et mises en garde
If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If symptoms worsen, consult a health care practitioner. If you have gallstones or a bile duct obstruction, consult a health care practitioner prior to use. If you have stomach ulcers or excess stomach acid, consult a health care practitioner prior to use.
Source
Official Health Canada record, licence 80089441
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.